Platycodin D reduces PD ‐ L1 levels by inhibiting LXR ‐β activity and combines with nintedanib to enhance the tumor‐killing effect of T cells
FEBS Letters · 2024
DOI: 10.1002/1873-3468.15034 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Letters, 2024. Verfasst von Jin Lei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Biology, East China University of Science and Technology, Shanghai, China. Hauptthemen laut MEDLINE: Liver X Receptors, Triterpenes, B7-H1 Antigen, Saponins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Zhejiang Fonow Medicine Co., Ltd..
Abstract (Originalsprache)
Most tumors are resistant to programmed cell death protein 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) checkpoint inhibitors, which may be due to impaired antigen presentation resulting from the downregulation of major histocompatibility complex class I (MHC‐I) expression on tumor cells. We observed that platycodin D (PD), polygalacin D, and platycodin D2, which are plant‐derived triterpenoid saponins, significantly reduced PD‐L1 levels. RNA sequencing and the PharmMapper database analysis identified liver X receptor β (LXR‐β) as a potential PD target. Further studies showed that PD reduces PD‐L1 levels by binding to LXR‐β and inhibiting LXR‐β activity. Coadministration of PD and nintedanib, known to upregulate MHC‐I expression, enhanced tumor recognition and killing by T cells. This study provides new insights into PD applications and mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Applied Biology, East China University of Science and Technology, Shanghai, China.
- ECUST-FONOW Joint Research Center for Innovative Medicines, East China University of Science and Technology, Shanghai, China.
- New Drug R&D Center, Zhejiang Fonow Medicine Co., Ltd., Dongyang, China.
- Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, China.
ORCID-Profile: Jian Zhao, Fu-Jun Wang
Förderung
- National Natural Science Foundation of China
- Zhejiang Fonow Medicine Co., Ltd.
Zitieren
APA
Lei, J., Cao, X. W., Li, P. F., Zhao, J., & Wang, F. J. (2024). Platycodin D reduces PD ‐ L1 levels by inhibiting LXR ‐β activity and combines with nintedanib to enhance the tumor‐killing effect of T cells. FEBS Letters. https://doi.org/10.1002/1873-3468.15034
Vancouver
Lei J, Cao XW, Li PF, Zhao J, Wang FJ. Platycodin D reduces PD ‐ L1 levels by inhibiting LXR ‐β activity and combines with nintedanib to enhance the tumor‐killing effect of T cells. FEBS Letters. 2024. doi:10.1002/1873-3468.15034
BibTeX
@article{Lei2024,
author = {Lei, Jin and Cao, Xue-Wei and Li, Peng-Fei and Zhao, Jian and Wang, Fu-Jun},
title = {Platycodin D reduces PD ‐ L1 levels by inhibiting LXR ‐β activity and combines with nintedanib to enhance the tumor‐killing effect of T cells},
journal = {FEBS Letters},
year = {2024},
doi = {10.1002/1873-3468.15034}
}
EUVIMED